William Calhoun – Projects/Grants — UTMB Health Research Expert Profiles

View Scopus Profile

Emailwjcalhouutmbedu

h-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

2 Active
72 Completed

1 - 50 out of 74 results

Active

Calhoun - Subproject
Calhoun, W.
2/1/23 → 1/31/24
Project: Other project
A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)
Calhoun, W.
Sanofi US Services Inc
6/6/22 → 6/5/27
Project: Other project
Completed

EXPLORATORY STUDY OF THE PREVALENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
Calhoun, W.
Pulmatrix, Inc.
9/8/22 → 9/7/23
Project: Other project
Calhoun Subproject
Calhoun, W.
2/1/22 → 1/31/23
Project: Other project
Calhoun Subproject
Calhoun, W.
2/1/22 → 1/31/23
Project: Other project
Calhoun Subproject
Calhoun, W.
2/1/21 → 1/31/23
Project: Other project
Calhoun Subproject
Calhoun, W.
2/1/21 → 1/31/22
Project: Other project
Establishing the Prevalence of Allergic Bronchopulmonary Aspergillosis
Calhoun, W.
12/21/20 → 12/1/22
Project: Other project
Establishing the Prevalence of Allergic Bronchopulmonary Aspergillosis
Calhoun, W.
Pulmatrix, Inc.
12/21/20 → 12/1/22
Project: Other project
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation
Calhoun, W.
Sanofi US Services Inc
11/7/19 → 11/6/22
Project: Other project
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammatio
Calhoun, W.
11/7/19 → 11/6/22
Project: Other project
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation
Calhoun, W.
11/7/19 → 11/6/22
Project: Other project
Study D3250C00059: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK)
Calhoun, W.
8/19/19 → 8/18/23
Project: Other project
Study D3250C00059: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK)
Calhoun, W.
8/19/19 → 8/18/21
Project: Other project
Study D3250C00059: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK)
Calhoun, W.
AstraZeneca LP
8/19/19 → 8/18/23
Project: Other project
A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older
Calhoun, W.
7/22/19 → 7/21/21
Project: Other project
A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older
Calhoun, W.
7/22/19 → 7/21/21
Project: Other project
A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older
Calhoun, W.
Bond Avillion 2 Development LP
7/22/19 → 7/21/21
Project: Other project
Calhoun Subproject
Calhoun, W.
2/10/19 → 1/31/21
Project: Other project
Calhoun Subproject
Calhoun, W.
2/10/19 → 1/31/21
Project: Other project
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma control
Calhoun, W.
2/6/19 → 2/5/22
Project: Other project
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma control
Calhoun, W.
AstraZeneca LP
2/6/19 → 2/5/22
Project: Other project
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma control
Calhoun, W.
2/6/19 → 2/5/22
Project: Other project
A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ß2 Ag
Calhoun, W.
10/19/18 → 10/18/20
Project: Other project
A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ß2 Ag
Calhoun, W.
10/19/18 → 10/18/20
Project: Other project
A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ß2 Ag
Calhoun, W.
AstraZeneca LP
10/19/18 → 10/18/20
Project: Other project
Protocol #GSK3772847: A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma
Calhoun, W.
8/29/18 → 8/28/20
Project: Other project
Protocol #GSK3772847: A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma
Calhoun, W.
8/29/18 → 8/28/20
Project: Other project
Protocol #GSK3772847: A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma
Calhoun, W.
Parexel International
8/29/18 → 8/28/20
Project: Other project
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer
Calhoun, W.
4/25/18 → 4/24/21
Project: Other project
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer
Calhoun, W.
Exact Sciences Corp
4/25/18 → 4/24/21
Project: Other project
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer
Calhoun, W.
4/25/18 → 4/24/21
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benrali21Jmab 30 mg sc in Patients with Sewre Asthma Uncontrolled on Standard of care Treatment
Calhoun, W.
10/12/17 → 10/11/19
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Studyto Evaluate the Safety and Efficacy of Benrali21Jmab 30 mg sc in Patients with Sewre Asthma Uncontrolled on Standard of care Treatment
Calhoun, W.
10/12/17 → 10/11/19
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Studyto Evaluate the Safety and Efficacy of Benrali21Jmab 30 mg sc in Patients with Sewre Asthma Uncontrolled on Standard of care Treatment
Calhoun, W.
AstraZeneca LP
10/12/17 → 10/11/19
Project: Other project
Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study
Calhoun, W.
12/7/16 → 12/6/21
Project: Other project
Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study)
Calhoun, W.
12/7/16 → 12/6/22
Project: Other project
Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study)
Calhoun, W.
GlaxoSmithKline Pharmaceuticals
12/7/16 → 12/6/22
Project: Other project
A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care for the treatment of acute respiratory exacerbations o
Calhoun, W.
6/15/16 → 6/14/18
Project: Other project
A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care for the treatment of acute respiratory exacerbations o
Calhoun, W.
6/15/16 → 6/14/18
Project: Other project
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 12 WEEKS IN SUBJECTS WITH PERSISTENT MODERATE TO SEVERE ASTHMA WHO REMAIN
Calhoun, W.
12/4/14 → 12/3/16
Project: Other project
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 12 WEEKS IN SUBJECTS WITH PERSISTENT MODERATE TO SEVERE ASTHMA WHO REMAIN
Calhoun, W.
Pfizer, Inc.
12/4/14 → 12/3/16
Project: Other project
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 12 WEEKS IN SUBJECTS WITH PERSISTENT MODERATE TO SEVERE ASTHMA WHO REMAIN
Calhoun, W.
12/4/14 → 12/3/16
Project: Other project
Protocol D3251C00003: A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase lll study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmon
Calhoun, W.
9/10/14 → 9/9/18
Project: Other project
Protocol D3251C00003: A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase lll study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmon
Calhoun, W.
9/10/14 → 9/9/18
Project: Other project
Protocol D3251C00003: A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase lll study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmon
Calhoun, W.
AstraZeneca LP
9/10/14 → 9/9/18
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled,Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-353) to Reduce Oral Corticosteroid Use in Patients with Uncontrolled Asthma on High Dose Inhaled Corticosteroid plus Long-
Calhoun, W.
7/15/14 → 12/31/16
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled,Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-353) to Reduce Oral Corticosteroid Use in Patients with Uncontrolled Asthma on High Dose Inhaled Corticosteroid plus Long-
Calhoun, W.
7/15/14 → 7/14/16
Project: Other project
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled,Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-353) to Reduce Oral Corticosteroid Use in Patients with Uncontrolled Asthma on High Dose Inhaled Corticosteroid plus Long-
Calhoun, W.
AstraZeneca LP
7/15/14 → 12/31/16
Project: Other project
A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting ß2 Agonist in Patients with Uncontrolled Asthma (SIRO
Calhoun, W.
AstraZeneca LP
6/18/14 → 6/17/16
Project: Other project